These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 30007958

  • 1. Transarterial Chemoembolization (TACE) Using Mitomycin with or without Irinotecan for Hepatocellular Carcinoma in European Patients.
    Gruber-Rouh T, Kamal A, Eichler K, Naguib NN, Beeres M, Langenbach M, Vogl TJ.
    Oncol Res Treat; 2018; 41(7-8):438-442. PubMed ID: 30007958
    [Abstract] [Full Text] [Related]

  • 2. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
    Gruber-Rouh T, Schmitt C, Naguib NNN, Nour-Eldin NA, Eichler K, Beeres M, Vogl TJ.
    BMC Cancer; 2018 Feb 14; 18(1):188. PubMed ID: 29444653
    [Abstract] [Full Text] [Related]

  • 3. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
    Niessen C, Unterpaintner E, Goessmann H, Schlitt HJ, Mueller-Schilling M, Wohlgemuth WA, Stroszczynski C, Wiggermann P.
    J Vasc Interv Radiol; 2014 Feb 14; 25(2):240-7. PubMed ID: 24291001
    [Abstract] [Full Text] [Related]

  • 4. Single- versus Triple-Drug Chemoembolization for Hepatocellular Carcinoma: Comparing Outcomes by Toxicity, Imaging Response, and Survival.
    Mouli SK, Hickey R, Thornburg B, Sato KT, Desai K, Gabr A, Kallini JR, Niemeri H, Kircher S, Mulcahy MF, Benson Iii AB, Gupta R, Salem R, Lewandowski RJ.
    J Vasc Interv Radiol; 2016 Sep 14; 27(9):1279-1287. PubMed ID: 27062355
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ, Langenbach MC, Hammerstingl R, Albrecht MH, Chatterjee AR, Gruber-Rouh T.
    Hepatol Int; 2021 Jun 14; 15(3):685-694. PubMed ID: 34043158
    [Abstract] [Full Text] [Related]

  • 6. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC.
    AJR Am J Roentgenol; 2016 Mar 14; 206(3):645-54. PubMed ID: 26901023
    [Abstract] [Full Text] [Related]

  • 7. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
    Maeda N, Osuga K, Higashihara H, Tomoda K, Mikami K, Nakazawa T, Nakamura H, Tomiyama N.
    Cardiovasc Intervent Radiol; 2012 Feb 14; 35(1):82-9. PubMed ID: 21203761
    [Abstract] [Full Text] [Related]

  • 8. Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma.
    Vogl TJ, Naguib NN, Nour-Eldin NE, Farshid P, Lehnert T, Gruber-Rouh T, Engels KS.
    Acad Radiol; 2012 Apr 14; 19(4):434-9. PubMed ID: 22265853
    [Abstract] [Full Text] [Related]

  • 9. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
    Orlacchio A, Chegai F, Roma S, Merolla S, Bosa A, Francioso S.
    Radiol Med; 2020 Jan 14; 125(1):98-106. PubMed ID: 31583558
    [Abstract] [Full Text] [Related]

  • 10. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
    Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R.
    Eur J Gastroenterol Hepatol; 2012 Apr 14; 24(4):437-43. PubMed ID: 22261548
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the relationship between hepatocellular carcinoma location and transarterial chemoembolization efficacy.
    Miki I, Murata S, Uchiyama F, Yasui D, Ueda T, Sugihara F, Saito H, Yamaguchi H, Murakami R, Kawamoto C, Uchida E, Kumita SI.
    World J Gastroenterol; 2017 Sep 21; 23(35):6437-6447. PubMed ID: 29085193
    [Abstract] [Full Text] [Related]

  • 12. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
    Gross A, Albrecht T.
    Cardiovasc Intervent Radiol; 2020 Mar 21; 43(3):402-410. PubMed ID: 31705244
    [Abstract] [Full Text] [Related]

  • 13. Lipiodol trans-arterial chemoembolization of hepatocellular carcinoma with idarubicin: first experience.
    Favelier S, Boulin M, Hamza S, Cercueil JP, Cherblanc V, Lepage C, Hillon P, Chauffert B, Krausé D, Guiu B.
    Cardiovasc Intervent Radiol; 2013 Aug 21; 36(4):1039-46. PubMed ID: 23224215
    [Abstract] [Full Text] [Related]

  • 14. A novel treatment strategy using indocyanine green for transarterial chemoembolization in BCLC stage C hepatocellular carcinoma.
    Mei J, Li SH, Wang QX, Zhong XP, Lu LH, Kan A, Wei W, Guo RP.
    Cancer Med; 2020 Jan 21; 9(1):62-76. PubMed ID: 31701652
    [Abstract] [Full Text] [Related]

  • 15. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
    Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, Liu HC, Li JL, Li YG, Li QL, Xiao H, Hong Y, Wang XH, Zhu HZ, Wu QF, Burns M, Liu C.
    Asian Pac J Cancer Prev; 2015 Jan 21; 16(1):245-51. PubMed ID: 25640360
    [Abstract] [Full Text] [Related]

  • 16. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies.
    Haubold J, Reinboldt MP, Wetter A, Li Y, Ludwig JM, Lange C, Wedemeyer H, Schotten C, Umutlu L, Theysohn J.
    Rofo; 2020 Sep 21; 192(9):862-869. PubMed ID: 32131109
    [Abstract] [Full Text] [Related]

  • 17. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
    He M, Li Q, Shen J, Tan G, Li Q, Lai J, Wei W, Zhang Y, Zou R, Chen M, Guo R, Shi M.
    Cancer Med; 2019 Aug 21; 8(9):4200-4213. PubMed ID: 31207163
    [Abstract] [Full Text] [Related]

  • 18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS, Lin CY, Chuang MT, Lin CY, Tsai YS, Wang CK, Ou MC.
    BMC Gastroenterol; 2018 Aug 03; 18(1):124. PubMed ID: 30075752
    [Abstract] [Full Text] [Related]

  • 19. Transarterial chemoembolization of hepatocellular carcinoma in a rat model: the effect of additional injection of survivin siRNA to the treatment protocol.
    Vogl TJ, Oppermann E, Qian J, Imlau U, Tran A, Hamidavi Y, Korkusuz H, Bechstein WO, Nour-Eldin NE, Gruber-Rouh T, Hammerstingl R, Naguib NN.
    BMC Cancer; 2016 May 23; 16():325. PubMed ID: 27215551
    [Abstract] [Full Text] [Related]

  • 20. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J, Liu Y, Ren Z, Zhang Y, Zhang M.
    J Cancer Res Ther; 2017 May 23; 13(5):767-772. PubMed ID: 29237901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.